2022Äê¹ú¼Ê·Î°©Ñо¿Ð­»á(IASLC)ÌìÏ·ΰ©´ó»á(WCLC)¼´½«ÓÚ2022Äê8ÔÂ6ÈÕÖÁ9ÈÕÔڰµØÀûάҲÄɾÙÐС£¡£¡£¡£¡£±¾´ÎÌìÏ·ΰ©´ó»á½«½ÒÏþÓÉÖйú´ó½ר¼Ò×÷ΪµÚÒ»×÷Õß»òͨѶ×÷ÕßµÄEGFR-TKIÏà¹ØЧ¹û¹²31ƪ£¬£¬£¬£¬£¬ÆäÖаüÀ¨º²É­ÖÆÒ©×ÔÖ÷Á¢ÒìÒ©¼×»ÇËá°¢ÃÀÌæÄáƬ(ÉÌÆ·Ãû£º°¢ÃÀÀÖ^?)Ïà¹ØЧ¹û21ƪ£¬£¬£¬£¬£¬Õ¼×ÜƪÊýµÄ68%£¬£¬£¬£¬£¬ÔÚËùÓÐEGFR-TKIÖÐÃûÁеÚÒ»¡£¡£¡£¡£¡£

WCLCÊÇÌìÏÂÉϹæÄ£×î´óµÄÖÂÁ¦Óڷΰ©ºÍÆäËüÐز¿¶ñÐÔÖ×ÁöµÄ¶àѧ¿ÆÖ×Áöѧ¾Û»á£¬£¬£¬£¬£¬Ã¿½ì¶¼»áÓжàÏîÖØ°õÁÙ´²Ñо¿Ð§¹ûÐû²¼²¢Óɴ˸üÐÂÁÙ´²Êµ¼ù¡£¡£¡£¡£¡£2022ÄêWCLC½«ÔÙ´ÎΪÀ´×ÔÈ«Çò100¶à¸ö¹ú¼ÒµÄÊýǧÃûרҵÈËÊ¿ÌṩÏßϽ»Á÷ƽ̨£¬£¬£¬£¬£¬ÅäºÏ̽Ìַΰ©ºÍÆäËüÐز¿¶ñÐÔÖ×ÁöµÄ×îÇ°ÑØÖÎÁÆÏ£Íû¡£¡£¡£¡£¡£

°¢ÃÀÌæÄáÊǺ²É­ÖÆÒ©×ÔÖ÷Ñз¢µÄÊ×ÆäÖйúÔ­´´Èý´úEGFR-TKI£¬£¬£¬£¬£¬Ò²ÊÇÈ«ÇòÊ×ÆäÖÐλÎÞÏ£ÍûÉúÑÄÆÚ(mPFS)Áè¼Ý1Äê(¶þÏßʹÓÃ)µÄÈý´úEGFR-TKI£¬£¬£¬£¬£¬ÒÀ¸½×¿Ô½µÄÁÆЧºÍÇå¾²ÐÔÓÅÊÆ£¬£¬£¬£¬£¬ÒѶà´Î»ñµÃ¹ú¼ÊȨÍþÈÏ¿É¡£¡£¡£¡£¡£2022Äê5Ô£¬£¬£¬£¬£¬°¢ÃÀÌæÄáAENEASÑо¿Ð§¹ûÔÚ¹ú¼ÊÖøÃûÖ×ÁöѧÆÚ¿¯¡¶ÁÙ´²Ö×ÁöѧÔÓÖ¾¡·(Journal of Clinical Oncology£¬£¬£¬£¬£¬JCO£¬£¬£¬£¬£¬IF:44.544)½ÒÏþ£¬£¬£¬£¬£¬×îÐÂÄÔתÒÆÑÇ×éÊý¾ÝÁÁÏàÃÀ¹úÁÙ´²Ö×Áöѧ»á(ASCO)Äê»á£¬£¬£¬£¬£¬ÔٴξªÑÞ¹ú¼ÊÖ×Áöѧ½ç¡£¡£¡£¡£¡£

Ϊ½øÒ»²½Ì½Ë÷°¢ÃÀÌæÄáÔڷΰ©Ï¸·ÖÁìÓòµÄÖÎÁÆDZÁ¦£¬£¬£¬£¬£¬»Ý¼°È«Çò¸ü¶àNSCLC»¼Õߣ¬£¬£¬£¬£¬»ùÓÚ°¢ÃÀÌæÄáÏÖÔÚÀֳɵÄÑз¢ÂÄÀú£¬£¬£¬£¬£¬ÆäÁÙ´²¼ÛÖµ»¹ÔÚ½øÒ»²½ÍÚ¾òÖУ¬£¬£¬£¬£¬°üÀ¨°¢ÃÀÀÖ^?ÍŽẬ²¬Ë«Ò©»¯ÁÆÒ»ÏßÖÎÁÆÓÐÃô¸ÐÍ»±äNSCLC¡¢¸¨ÖúÖÎÁÆNSCLCµÈ˳Ӧ֢µÄ¶à¸öÁÙ´²Ñо¿£¬£¬£¬£¬£¬½«Îª¸ü¶àNSCLC»¼ÕßÌṩ´ÓÔçÆÚµ½ÍíÆÚ£¬£¬£¬£¬£¬´ÓΧÊÖÊõÆÚ¸¨ÖúÖÎÁÆ¡¢¶þÏß¼°ºóÏßÖÎÁƵ½Ò»ÏßÖÎÁƵÈÈ«·½Î»¶àά¶ÈµÄÓÃÒ©¼Æ»®¡£¡£¡£¡£¡£

±¾½ìWCLCÉÏ£¬£¬£¬£¬£¬°¢ÃÀÌæÄá¶à´ï21ƪժҪÈëÑ¡£¬£¬£¬£¬£¬°üÀ¨7ƪͨÀýÕªÒª(Ñо¿Êý¾Ý)¡¢3ƪ²¡Àý±¨µÀÒÔ¼°11ƪÕýÔÚ¾ÙÐÐÖеÄÁÙ´²Ñо¿£¬£¬£¬£¬£¬½«´øÀ´°¢ÃÀÌæÄáÔÚ·ÇСϸ°û·Î°©(NSCLC)°ÐÏòÍŽáÖÎÁÆ¡¢ÄÔ(Ĥ)תÒÆÖÎÁƵÈÆ«Ïò×îÐÂÑо¿Ï£Íû¡£¡£¡£¡£¡£

ͨÀýÕªÒª

ÕªÒª±àºÅ£ºEP08.02-003

Aumolertinib Plus Chemotherapy as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation and ctDNA Cleared Analysis

°¢ÃÀÌæÄáÍŽữÁÆÒ»ÏßÖÎÁÆEGFRÍ»±äÍíÆڷΰ©

×÷ÕߣºÀîÑàΡ  Ìì½òÒ½¿Æ´óѧÖ×ÁöÒ½Ôº

¼ò½é£º±¾Ñо¿£¨NCT04646824£©ÊÇÒ»Ïîµ¥±Û¡¢µ¥ÖÐÐÄ¡¢IIÆÚÁÙ´²Ñо¿£¬£¬£¬£¬£¬Ö¼ÔÚÊӲ찢ÃÀÌæÄáÍŽữÁÆÒ»ÏßÖÎÁÆ¢ó-¢ôÆÚEGFRÍ»±äNSCLC»¼ÕßµÄÁÆЧºÍÇå¾²ÐÔ¡£¡£¡£¡£¡£ÖÎÁƼƻ®Îª°¢ÃÀÌæÄá110mg/dÍŽáÅàÃÀÇúÈüºÍ¿¨²¬4ÖÜÆÚ£¬£¬£¬£¬£¬ºó°¢ÃÀÌæÄáÍŽáÅàÃÀÇúÈüά³ÖÖÎÁÆ£¬£¬£¬£¬£¬Ö±ÖÁ·ºÆ𲻿ÉÄÍÊܵĶ¾ÐÔºÍÖ×ÁöÏ£Íû¡£¡£¡£¡£¡£×èÖ¹µ½2021Äê11Ô£¬£¬£¬£¬£¬¹²ÕÐļÁË34Àý»¼Õߣ¬£¬£¬£¬£¬×ÜÈËȺORR88.2%£¬£¬£¬£¬£¬ÆäÖÐ19Àý»ùÏßÄÔתÒÆ»¼ÕßORR89.4%£¬£¬£¬£¬£¬ºÏ²¢TP53ÑÇ×éORR 92.3%£¨12/13£©£¬£¬£¬£¬£¬78.6%£¨22/28£©µÄ»¼Õß½ÓÊÜÖÎÁÆ2-4¸öÖÜÆÚºó·ºÆðÁËctDNAÇåÁ㣬£¬£¬£¬£¬¶¯Ì¬ÇåÁãÓë·ñÓëORRÁÆЧ¸ß¶ÈÏà¹Ø£¨ORR90.9%vs 33.3%£©£¬£¬£¬£¬£¬ÇÒÇå¾²ÐÔ¿É¿Ø£¬£¬£¬£¬£¬×î³£¼ûµÄ²»Á¼ÊÂÎñAEÊÇÖÐÐÔÁ£Ï¸°ûïÔÌ­¡¢·¦Á¦ºÍÑáʳµÈ£¬£¬£¬£¬£¬AE¶àÓ뻯ÁÆÏà¹Ø£¬£¬£¬£¬£¬Î´±¬·¢Ö°¢ÃÀÌæÄáÖÐÖ¹ÖÎÁƵÄAE¡£¡£¡£¡£¡£

ÕªÒª±àºÅ£ºEP08.02-004

Aumolertinib in Treatment-Na?ve EGFR-mutant NSCLC Patients with Brain Metastases: Primary Efficacy and Safety Data from the ARTISTRY

°¢ÃÀÌæÄáÒ»ÏßÖÎÁÆEGFRÍ»±äNSCLC°éÄÔתÒÆ£¨ARTISTRYÑо¿ÐÐÁÐ1£©

×÷ÕߣºÍõ»Û¾ê  ºÓÄÏÊ¡Ö×ÁöÒ½Ôº

¼ò½é£ºARTISTRYÑо¿£¨NCT04778800£©Ö¼ÔÚÊÓ²ì²î±ð¼ÁÁ¿°¢ÃÀÌæÄá¶Ô EGFRÍ»±äNSCLCÄÔ/ÄÔĤתÒÆ»¼ÕßµÄÁÆЧºÍÇå¾²ÐÔ£¬£¬£¬£¬£¬ÆäÐÐÁÐ1ÖÐÄÔʵÖÊתÒÆ»¼Õß½ÓÊÜ°¢ÃÀÌæÄá110mg/dÒ»ÏßÖÎÁÆ£¬£¬£¬£¬£¬µ±»¼Õß½ö­ÄÚÏ£Íû¶øÆäÓಿλδϣÍûʱ£¬£¬£¬£¬£¬°¢ÃÀÌæÄá¼ÁÁ¿µÝÔöÖÁ165mg¡£¡£¡£¡£¡£×èÖ¹2022Äê3Ô£¬£¬£¬£¬£¬¹²Èë×é14Àý»¼Õߣ¬£¬£¬£¬£¬ÆäÖÐ12Àý»¼ÕßÄÉÈëcFASÆÊÎö¼¯£¨¡Ý1¸öCNS¿ÉÕÉÁ¿²¡ÔîºÍ/»ò²»¿ÉÕÉÁ¿²¡Ô£¬£¬£¬£¬£¬10Àý»¼ÕßÄÉÈëcEFRÆÊÎö¼¯£¨¡Ý1¸öCNS¿ÉÕÉÁ¿²¡Ô¡£¡£¡£¡£¡£iORRÔÚcFASºÍcEFRÖл®·ÖΪ66.7%ºÍ80%£¬£¬£¬£¬£¬iDCRÔÚÁ½¸öÆÊÎö¼¯ÖоùΪ100%¡£¡£¡£¡£¡£3Àý½ÓÊÜ165mg°¢ÃÀÌæÄáÖÎÁƵĻ¼ÕßÖУ¬£¬£¬£¬£¬iDCR´ï100%¡£¡£¡£¡£¡£ÕûÌåÇå¾²ÐÔÓÅÒ죬£¬£¬£¬£¬Î´¼û3¼¶ÒÔÉϲ»Á¼ÊÂÎñ¡£¡£¡£¡£¡£

ÕªÒª±àºÅ£ºEP08.02-038

Study of First-Line Aumolertinib Plus Bevacizumab and Pemetrexed Treated NSCLC with EGFR Mutation and Brain Metastasis

°¢ÃÀÌæÄáÍŽᱴ·¥Öéµ¥¿¹ºÍ»¯ÁÆÒ»ÏßÖÎÁÆEGFRÍ»±äNSCLC°éÄÔתÒÆ

¼ò½é£ºSpringlung150B(ChiCTR2000035591)ÊÇÒ»ÏîÇ°Õ°¡¢¶àÖÐÐÄÁÙ´²Ñо¿£¬£¬£¬£¬£¬ÄÉÈëδ¾­ÖÎÁƵÄÍíÆÚEGFRÍ»±äÄÔתÒÆ·ÎÏÙ°©»¼Õߣ¬£¬£¬£¬£¬½ÓÊÜ°¢ÃÀÌæÄá(110mg/d)ÍŽᱴ·¥Öéµ¥¿¹£¨7.5mg/kg£©¡¢ÅàÃÀÇúÈû£¨500mg/©O£©4-6¸öÖÜÆÚÖÎÁƺ󣬣¬£¬£¬£¬Ëæ»ú·ÖΪ°¢ÃÀÌæÄáµ¥Ò©×飬£¬£¬£¬£¬°¢ÃÀÌæÄáÍŽᱴ·¥µ¥¿¹×é»ò°¢ÃÀÌæÄáÍŽáÅàÃÀÇúÈû×é¡£¡£¡£¡£¡£×èÖ¹µ½2021Äê11Ô£¬£¬£¬£¬£¬¶Ô10Àý»¼Õß¾ÙÐÐ4-6ÖÜÆÚÍŽáÖÎÁƵÄÁÆЧÆÀ¹À¡£¡£¡£¡£¡£10Àý»¼Õß¾ùµÖ´ïPR£¬£¬£¬£¬£¬×ÜÌåORRΪ80%, DCRΪ100%£»£»£»£»£»£»£»£»Â­ÄÚiORRΪ90%£¬£¬£¬£¬£¬iDCRΪ 100%¡£¡£¡£¡£¡£»£»£»£»£»£»£»£»¼ÕßÇå¾²ÐÔÓÅÒ죬£¬£¬£¬£¬×î³£¼û²»Á¼·´Ó¦ÎªÆ¤Õ40%£©£¬£¬£¬£¬£¬ÎÞ3¼¶ÒÔÉϲ»Á¼·´Ó¦¡£¡£¡£¡£¡£

ÕªÒª±àºÅ£ºEP08.02-050

A Retrospective Study of Aumolertinib in Combination with Bevacizumab for EGFR-mutated NSCLC with the Presence of Leptomeningeal Metastasis

°¢ÃÀÌæÄáÍŽᱴ·¥Öéµ¥¿¹ÖÎÁÆEGFRÍ»±äNSCLC°éÄÔĤתÒƵĻØÊ×ÐÔÑо¿

×÷Õߣº·½Éê´æ  ÄϾ©ÊÐÐØ¿ÆÒ½Ôº

¼ò½é£ºÒ»Ïî°¢ÃÀÌæÄáÍŽᱴ·¥Öéµ¥¿¹ÖÎÁÆEGFRÍ»±ä°éÓÐÄÔĤתÒƵÄNSCLCµÄ»ØÊ×ÐÔÑо¿£¬£¬£¬£¬£¬¹²ÄÉÈëÄϾ©ÐØ¿ÆÒ½Ôº5Àý½ÓÊÜ°¢ÃÀÌæÄá(110 mg/Ìì)ÍŽᱴ·¥Öéµ¥¿¹(7.5 mg/kg, 21ÌìÖÜÆÚ)ÖÎÁƵÄEGFRÍ»±ä°éÓÐÄÔĤתÒƵÄNSCLC»¼Õߣ¬£¬£¬£¬£¬ÖÐλÖÎÁÆʱ¼ä11¸öÔ£¬£¬£¬£¬£¬ÖÎÁÆÇ°ÖÐλPSÆÀ·ÖΪ4·Ö£¬£¬£¬£¬£¬ÖÎÁƺóÖÐλPSÆÀ·ÖΪ1·Ö¡£¡£¡£¡£¡£ORR´ï80%£¬£¬£¬£¬£¬DCR´ï100%£¬£¬£¬£¬£¬Â­ÄÚORR´ï100%¡£¡£¡£¡£¡£ÍŽáÖÎÁÆ2¸öԺ󣬣¬£¬£¬£¬5Àý»¼Õß¾ùÐЭÄԴŹ²Õñ³ÉÏñ(MRI)¼ì²é£¬£¬£¬£¬£¬LMÏÔ×ÅïÔÌ­£¬£¬£¬£¬£¬Ëæ×ÅÖÎÁƵļÌÐø£¬£¬£¬£¬£¬LMÒ»Á¬»º½â£¬£¬£¬£¬£¬5Àý»¼Õß¾ùÎÞÈ«Éí»òLM²¡±äÏ£Íû£¬£¬£¬£¬£¬Çå¾²ÐÔÓÅÒì¡£¡£¡£¡£¡£

ÕªÒª±àºÅ£ºEP08.02-069

A Retrospective Study of Aumolertinib Monotherapy or Combination Therapy Treated EGFR-mutated NSCLC Patients with Leptomeningeal Metastases

°¢ÃÀÌæÄáµ¥Ò©»òÍŽáÖÎÁÆEGFRÍ»±äNSCLC°éÄÔĤתÒƵĻØÊ×ÐÔÑо¿

×÷ÕߣºÀîÐÑÑÇ  Ö£ÖÝ´óѧµÚÒ»Á¥ÊôÒ½Ôº

¼ò½é£º±¾Ñо¿ÊÇÒ»Ïî°¢ÃÀÌæÄáµ¥Ò©»òÍŽáÆäËüÒ©ÎïÖÎÁÆEGFRÍ»±äÇÒ°éÓÐÄÔĤתÒÆNSCLCµÄ»ØÊ×ÐÔÑо¿¡£¡£¡£¡£¡£¹²ÄÉÈëÖ£ÖÝ´óѧµÚÒ»Á¥ÊôÒ½Ôº11Àý»¼Õߣ¬£¬£¬£¬£¬½ÓÊÜ°¢ÃÀÌæÄá(110mg/Ìì)»òÍŽữÁÆ£¨»¯ÁÆ»ò±´·¥µ¥¿¹£©Ö±ÖÁ¼²²¡Ï£Íû»ñ²»ÄÍÊÜ¡£¡£¡£¡£¡£Ð§¹ûÏÔʾ£º²¿·Ö»º½â(PR)6Àý(54.5%)£¬£¬£¬£¬£¬²¡ÇéÎȹÌ(SD)3Àý(27.3%)£¬£¬£¬£¬£¬ORRΪ54.5%(6/11)£¬£¬£¬£¬£¬DCRΪ81.8%(9/11)¡£¡£¡£¡£¡£ËùÓл¼ÕßµÄÖÐλPFSΪ8.1¸öÔ¡£¡£¡£¡£¡£ÑÇ×éÆÊÎö£¬£¬£¬£¬£¬19delºÍL858R»¼ÕßÖÐλPFS»®·ÖΪ11ºÍ7.6¸öÔ£¬£¬£¬£¬£¬EGFRÍ»±äÑôÐԺϲ¢TP53µÄÖÐλPFSΪ7.3¸öÔ£¬£¬£¬£¬£¬ÎÞTP53ºÏ²¢Í»±äµÄÖÐλPFSΪ11¸öÔ¡£¡£¡£¡£¡£

ÕªÒª±àºÅ£ºEP08.02-154

Aumolertinib Plus Anlotinib as 1st-Line Treatment for EGFR Mutant Non-Small Cell Lung Cancer: A Phase II Trial

°¢ÃÀÌæÄáÍŽᰲÂÞÌæÄáÒ»ÏßÖÎÁÆEGFRÍ»±äNSCLC

×÷Õߣº³Â»ªÁÖ  ¹ã¶«Ò½¿Æ´óѧÁ¥ÊôÒ½Ôº

¼ò½é£º±¾Ñо¿ÊÇÒ»Ïîµ¥±Û¡¢µ¥ÖÐÐÄ¡¢IIÆÚÁÙ´²Ñо¿£¬£¬£¬£¬£¬ÄÉÈëδ¾­ÖÎÁƵÄÍíÆÚ EGFRÍ»±äNSCLC»¼Õß¡£¡£¡£¡£¡£½ÓÊÜ°¢ÃÀÌæÄá110mg/dÍŽᰲÂÞÌæÄá12mg/dÖÎÁÆ£¬£¬£¬£¬£¬Ö±ÖÁ·ºÆ𲻿ÉÄÍÊܵĶ¾ÐÔºÍÖ×ÁöÏ£Íû¡£¡£¡£¡£¡£×èÖ¹µ½2022Äê3Ô£¬£¬£¬£¬£¬¹²ÕÐļÁË11Àý»¼Õߣ¬£¬£¬£¬£¬ÆäÖÐÄÔתÒÆ7Àý£¨63.6%£©¡£¡£¡£¡£¡£11Àý»¼Õß¾ùµÖ´ïPR£¬£¬£¬£¬£¬×ÜÌåORRΪ100%(11/11)£»£»£»£»£»£»£»£»7ÀýÄÔתÒÆ»¼Õß½ÓÊÜ­Äڰв¡ÔîÆÀ¹À£¬£¬£¬£¬£¬ÆäÖÐ5ÀýµÖ´ïPR£¬£¬£¬£¬£¬2ÃûSD£¬£¬£¬£¬£¬iORRΪ71.4%(5/7)£¬£¬£¬£¬£¬iDCRΪ100%(7/7)¡£¡£¡£¡£¡£Ã»Óл¼ÕßÒò²»Á¼·´Ó¦Í£Ò©£¬£¬£¬£¬£¬Çå¾²ÐÔÓÅÒì¡£¡£¡£¡£¡£

ÕªÒª±àºÅ£ºEP08.02-169

Research of Aumolertinib Combined with Bevacizumab for Advanced NSCLC Lung Cancer with EGFR Sensitive Mutation

°¢ÃÀÌæÄáÍŽᱴ·¥Öéµ¥¿¹Ò»ÏßÖÎÁÆEGFRÍ»±äÍíÆÚNSCLC

×÷ÕߣºÖÓµîʤ  Ìì½òÒ½¿Æ´óѧ×ÜÒ½Ôº

¼ò½é£º±¾Ñо¿ÊÇÒ»Ïîµ¥±Û¡¢µ¥ÖÐÐÄ¡¢IIÆÚÁÙ´²Ñо¿£¬£¬£¬£¬£¬ÄÉÈëδ¾­ÖÎÁƵĢôÆÚ EGFRÍ»±äNSCLC»¼Õß¡£¡£¡£¡£¡£ÖÎÁƼƻ®Îª°¢ÃÀÌæÄá110mg/dÍŽᱴ·¥Öéµ¥¿¹7.5 mg/kg Q3W£¬£¬£¬£¬£¬Ö±ÖÁ·ºÆ𲻿ÉÄÍÊܵĶ¾ÐÔºÍÖ×ÁöÏ£Íû¡£¡£¡£¡£¡£×èÖ¹µ½2022Äê4Ô£¬£¬£¬£¬£¬¹²ÕÐļÁË19Àý»¼Õߣ¬£¬£¬£¬£¬ÆäÖÐ15Àý¿ÉÆÀ¹ÀÁÆЧ£¬£¬£¬£¬£¬×ÜÈËȺORR 66.7%£¬£¬£¬£¬£¬DCR 93.3%¡£¡£¡£¡£¡£ÆäÖÐ12Àý»ùÏßÄÔתÒÆ»¼ÕßORR 83.3%£¬£¬£¬£¬£¬8ÀýÄÔתÒÆ»¼Õß½ÓÊÜ­Äڰв¡ÔîÆÀ¹À£¬£¬£¬£¬£¬iORRΪ87.5%£¬£¬£¬£¬£¬iDCRΪ100%¡£¡£¡£¡£¡£3Àý»¼Õß·ºÆð3¼¶AE£¬£¬£¬£¬£¬1Àý»¼ÕßÒòÐØÍ´Í£Óñ´·¥Öéµ¥¿¹¡£¡£¡£¡£¡£

²¡Àý±¨µÀ

ÕªÒª±àºÅ£ºEP08.02-002

Aumolertinib in the Treatment of Activated EGFR Mutation Advanced NSCLC Patients with Interstitial Pneumonia

°ÂÏ£ÌæÄáÓÕ·¢¼äÖÊÐÔ·ÎÑ׺óת°¢ÃÀÌæÄáÖÎÁÆ

×÷ÕߣºÌ·½à  ËÕÖÝÊÐÁ¢Ò½Ôº

¼ò½é£ºÒ»Àý81ËêÄÐÐÔNSCLC»¼Õߣ¬£¬£¬£¬£¬2013Äê±»Õï¶ÏΪIBÆÚÏÙ°©(pT2aN0M0)¡£¡£¡£¡£¡£ÊÖÊõÖÎÁÆ3Äêºó¾±²¿¶à·¢Ö×´óÁÜͶºÏ£¬£¬£¬£¬£¬»ùÒò¼ì²âÌáÐÑEGFRÍâÏÔ×Ó19ȱʧ¡£¡£¡£¡£¡£¸Ã»¼Õß½ÓÊÜÁË1¸öÁƳ̵ıê×¼¼ÁÁ¿ÅàÃÀÇúÈûÍŽá˳²¬ÖÎÁÆ£¬£¬£¬£¬£¬ÒòÁÆЧ²»¼Ñ¸ÄΪ¼ª·ÇÌæÄá250mg/dÖÎÁÆ1¸öÔ£¬£¬£¬£¬£¬²¿·Ö»º½â£¬£¬£¬£¬£¬ºóÒò¸´·¢ÐÔÒ©ÎïÏà¹ØÐÔ¸ÎËðÉ˸ÄÓ𣿣¿£¿£¿£¿£¿£¿£¿ËÌæÄᣬ£¬£¬£¬£¬µÚÒ»´úEGFR-TKIsÖÎÁÆ»º½â38¸öÔºóÆ䲡ÇéÏ£Íû·ºÆðÁËT790MÍ»±ä¡£¡£¡£¡£¡£½ÓÊÜ°ÂÏ£ÌæÄᣨ80mg/d£©ÖÎÁÆ£¬£¬£¬£¬£¬²¿·Ö»º½â£¬£¬£¬£¬£¬4¸öÔº󱬷¢¼äÖÊÐÔ·ÎÑ×£¬£¬£¬£¬£¬Í£Ò©ºó»º½â£¬£¬£¬£¬£¬ÖØиøÒ©ºó¸´·¢£¬£¬£¬£¬£¬»»ÓÃ110mg/d°¢ÃÀÌæÄáÖÎÁÆ£¬£¬£¬£¬£¬ÁÆЧÎȹÌ£¬£¬£¬£¬£¬¼äÖÊÐÔ·ÎÑ×δ¸´·¢¡£¡£¡£¡£¡£

ÕªÒª±àºÅ£ºEP08.02-039

An Effective Treatment for EGFR-mutated Lung Adenocarcinoma with Symptomatic Leptomeningeal Metastases Using Aumolertinib

¸ß¼ÁÁ¿°¢ÃÀÌæÄáÖÎÁÆEGFRÍ»±ä·ÎÏÙ°©°éÓÐÖ¢×´µÄÄÔĤתÒÆ

×÷ÕߣºÕÅÐÂÓ  Ê׶¼Ò½¿Æ´óѧÁ¥Êô±±¾©ÐØ¿ÆÒ½Ôº

¼ò½é£ºÒ»Àý53ËêÅ®ÐÔ»¼ÕßÕï¶ÏΪ×ó·ÎÏÙ°©°éÄÔĤ¡¢ÄÔתÒÆ£¬£¬£¬£¬£¬EGFR 19del£¬£¬£¬£¬£¬³õÕïʱͷʹÍÂÄæÖ¢×´ÏÔ×Å£¬£¬£¬£¬£¬Â­ÄÚѹ´óÓÚ320mm H?O£¬£¬£¬£¬£¬PSÆÀ·Ö4·Ö£¬£¬£¬£¬£¬Óð¢ÃÀÌæÄá220mg/dÖÎÁÆ3ÌìºóÖ¢×´ÏÔןÃת£¬£¬£¬£¬£¬»¼Õß¿É×ÔÖ÷½øʳ£¬£¬£¬£¬£¬¸ÄΪͨÀý¼ÁÁ¿110mg/d£¬£¬£¬£¬£¬12Ììºó­ÄÚѹ½µÖÁÕý³£Öµ£¬£¬£¬£¬£¬PSÆÀ·Ö1·Ö¡£¡£¡£¡£¡£¿£¿£¿£¿£¿£¿£¿£Ë¼Á¿Ö×Áö¸ººÉÖØ£¬£¬£¬£¬£¬×îÏÈÍŽᱴ·¥Öéµ¥¿¹Î¬³ÖÖÎÁÆ£¬£¬£¬£¬£¬PFS´ï15¸öÔ£¬£¬£¬£¬£¬Çå¾²ÐÔÓÅÒì¡£¡£¡£¡£¡£

ÕªÒª±àºÅ£ºEP08.02-095

Successful Treatment of EGFR Exon 19 Deletion with TP53 and ERBB2 20ins Mutation in Stage IVB NSCLC Patient with Aumolertinib

°¢ÃÀÌæÄáÖÎÁÆEGFR 19ȱʧ°éTP53ºÍERBB2 20²åÈëÍ»±äIVBÆÚNSCLC

×÷ÕߣºÁõ´ºÁá  Ð½®Ò½¿Æ´óѧÁ¥ÊôÖ×ÁöÒ½Ôº

¼ò½é£ºÒ»Àý55Ë껼ÕßÕï¶ÏΪ¡°×ó·ÎÉÏÒ¶ÏÙ°©IVBÆÚ£¬£¬£¬£¬£¬Ë«²à·ÎÃÅ¡¢×ÝëõÁÜͶºÏ¡¢Ë«·Î¡¢¶à·¢¹ÇתÒÆ¡±£¬£¬£¬£¬£¬»ùÒò¼ì²âЧ¹ûÌáÐÑΪEGFR 19DelºÏ²¢TP53Í»±ä¡£¡£¡£¡£¡£»£»£»£»£»£»£»£»¼Õß¾ßÓÐÂýÐÔÒÒÐ͸ÎÑײ¡Ê·20ÓàÄê¡£¡£¡£¡£¡£Ò»ÏßÖÎÁƼƻ®£º¿Ú·þ¼ª·ÇÌæÄᣬ£¬£¬£¬£¬×î¼ÑÁÆЧPR£¬£¬£¬£¬£¬PFS1=9¸öÔ¡£¡£¡£¡£¡£Ëæºó·ºÆðз¢×ªÒÆÔ£¬£¬£¬£¬Ë¼Á¿¼²²¡Ï£Íû£¬£¬£¬£¬£¬ÔٴλùÒò¼ì²âÏÔʾERBB2 20ins²¢EGFR 19Del²¢TP53Í»±ä¡£¡£¡£¡£¡£¶þÏßÖÎÁƼƻ®£º»¼Õß¿Ú·þ°¢ÃÀÌæÄá110mg£¬£¬£¬£¬£¬·Î²¿²¡Ôî×î¼ÑÁÆЧPR£¬£¬£¬£¬£¬PFS 2=7¸öÔ£¬£¬£¬£¬£¬ÄÍÊÜÐԽϺ㬣¬£¬£¬£¬Î´·ºÆð¸Î¹¦Ð§ËðÉË¡£¡£¡£¡£¡£ºóÒòÔ­·¢²¡Ôî½ÏÇ°Ôö´ó£¬£¬£¬£¬£¬¾±²¿ºÍËø¹ÇÇø¶à·¢ÁÜͶºÏתÒÆ¡£¡£¡£¡£¡£ÔÚÈýÏßÖÎÁƼƻ®¡ª¡ªÑ¡ÔñA£«T£«C¼Æ»®£¨¿Ú·þ°¢ÃÀÌæÄá110mg£¬£¬£¬£¬£¬Í¬Ê±ÍŽáÅàÃÀÇúÈû6ÖÜÆںͱ´·¥Öéµ¥¿¹¡£¡£¡£¡£¡£Ô­·¢²¡ÔתÒÆÔî¾ùËõС£¬£¬£¬£¬£¬Ñ×ÐÔÉø͸ÎüÊÕ£¬£¬£¬£¬£¬ÕûÌåÁÆЧΪSD¡£¡£¡£¡£¡£ÈýÏßÖÎÁƺóµÄά³Ö¼Æ»®¡ª¡ª¼ÌÐø¿Ú·þ°¢ÃÀÌæÄá110mg£¬£¬£¬£¬£¬Í¬Ê±ÍŽᱴ·¥Öéµ¥¿¹£¬£¬£¬£¬£¬ÏÖÔÚPFS 3>13¸öÔ£¬£¬£¬£¬£¬¸Ã»¼ÕßÈÔÔÚËæ·ÃÖС£¡£¡£¡£¡£×ܽ᣺¸Ã»¼ÕßÏÖÔÚÕûÌåPFS£¾29¸öÔ£¬£¬£¬£¬£¬Ê¹ÓÃÒÔ°¢ÃÀÌæÄáΪ½¹µãµÄÖÎÁƼƻ®Ê±´ú£¬£¬£¬£¬£¬PFS£¾20¸öÔ£¬£¬£¬£¬£¬¼²²¡¿ØÖÆÓÅÒì¡£¡£¡£¡£¡£ÖÎÁÆÀú³ÌÖнö·ºÆð1-2¼¶²»Á¼·´Ó¦£¬£¬£¬£¬£¬²¿·Ö²»Á¼·´Ó¦Ë¼Á¿ÓëÍŽữÁÆÒ©ÎïÏà¹Ø£¬£¬£¬£¬£¬ÕûÌåÄÍÊÜÐÔÓÅÒì¡£¡£¡£¡£¡£

ÕýÔÚ¾ÙÐÐÖеÄÁÙ´²Ñо¿

ÕªÒª±àºÅ£ºEP08.02-001

Concurrent Aumolertinib and Cerebral Radiotherapy as First-Line Treatment for EGFR Mutated Non-small Cell Lung Cancer with Brain Metastases

°¢ÃÀÌæÄáÁªÌõÔ¼²½·ÅÁÆÒ»ÏßÖÎÁÆEGFRÍ»±äNSCLC°éÄÔתÒÆ

×÷ÕߣºÍõÓ±  ÖØÇì´óѧÁ¥ÊôÖ×ÁöÒ½Ôº

ÕªÒª±àºÅ£ºEP05.02-009

Aumolertinib Versus Erlotinib/Chemotherapy for Neoadjuvant Treatment of Stage IIIA EGFR-mutant NSCLC (ANSWER)

°¢ÃÀÌæÄá±ÈÕÕ¶òÂåÌæÄá»ò»¯ÁÆи¨ÖúÖÎÁÆEGFRÍ»±äIIIAÆÚNSCLC£¨ANSWERÑо¿£©

×÷ÕߣºÁºÎÄ»ª  ¹ãÖÝÒ½¿Æ´óѧÁ¥ÊôµÚÒ»Ò½Ôº

ÕªÒª±àºÅ£ºEP05.02-016

Aumolertinib after Adjuvant Chemotherapy/Radiotherapy in Stage pIIIA-N2 Non-Small-Cell Lung Cancer with EGFR Mutation

Êõºó¸¨Öú·Å»¯ÁÆÐò¹á°¢ÃÀÌæÄáÖÎÁÆEGFRÍ»±äpIIIA-N2ÆÚNSCLC

×÷ÕߣºÕÅ褠 ¹óÖÝÊ¡ÈËÃñÒ½Ôº

ÕªÒª±àºÅ£ºEP08.02-021

A Phase II Trial of Upfront Aumolertinib (HS-10296) plus Radiotherapy for EGFR Mutated Non-small-cell Lung Cancer Patients with Brain Metastases

°¢ÃÀÌæÄáÍŽá·ÅÁÆÖÎÁÆEGFRÍ»±äNSCLC°éÄÔתÒÆ

×÷Õߣͬıù  º¼ÖÝÊÐÖ×ÁöÒ½Ôº

ÕªÒª±àºÅ£ºEP08.02-051

High-dose Aumolertinib as First-line Treatment in Patients with Brain Metastases Associated with EGFR Mutated NSCLC

¸ß¼ÁÁ¿°¢ÃÀÌæÄáÒ»ÏßÖÎÁÆEGFRÍ»±äNSCLC°éÄÔתÒÆ

×÷Õߣº·¶ÔÆ  Õã½­Ê¡Ö×ÁöÒ½Ôº

ÕªÒª±àºÅ£ºEP08.02-057

Mechanism of Resistance to Second-Line Aumolertinib and Therapeutic Regime after Resistance

°¢ÃÀÌæÄá¶þÏßÖÎÁÆÄÍÒ©Æ×Ñо¿

×÷Õߣº·ëÁäöΠ Çൺ´óѧÁ¥ÊôÒ½Ôº

ÕªÒª±àºÅ£ºEP08.02-067

Concurrent Aumolertinib Plus Icotinib for First-Line Treatment of EGFR Mutated Non-small Cell Lung Cancer with Brain Metastases

°¢ÃÀÌæÄáÍŽá°£¿£¿£¿£¿£¿£¿£¿£¿ËÌæÄáÒ»ÏßÖÎÁÆEGFRÍ»±äNSCLCÄÔתÒÆ»¼Õß

×÷Õߣº»ÆÃÄ¾ê  ËÄ´¨´óѧ»ªÎ÷Ò½Ôº

ÕªÒª±àºÅ£ºEP08.02-077

Two Phase III Trials of Aumolertinib Plus Chemotherapy for NSCLC with EGFR and Concomitant non-EGFR Driver Genes /Tumor Suppressor Genes

°¢ÃÀÌæÄáÍŽữÁÆÒ»ÏßÖÎÁÆEGFRÍ»±äºÏ²¢·ÇEGFRÇý¶¯»ùÒòÍ»±ä/ÒÖ°©»ùÒòÍ»±äNSCLC£¨ACROSSÑо¿£©

×÷ÕߣºÍõ½à  Öйúҽѧ¿ÆѧԺÖ×ÁöÒ½Ôº

ÕªÒª±àºÅ£ºEP08.02-094

Aumolertinib as First-line Treatment in EGFR-Mutant Pulmonary Adenosquamous Carcinoma (ARISE): A Multicenter, Open-Label, Single-Arm Trial

°¢ÃÀÌæÄáÒ»ÏßÖÎÁÆEGFRÍ»±ä·ÎÏÙÁÛ°©£¨ARISEÑо¿£©

×÷ÕߣºÁÖ¸ù  ¸£½¨Ê¡Ö×ÁöÒ½Ôº

ÕªÒª±àºÅ£ºEP08.02-137

Prospective Study of Aumolertinib in NSCLC Patients with EGFR Sensitive Mutations Who Are Intolerant to Osimertinib Treatment

°¢ÃÀÌæÄáÖÎÁƾ­°ÂÏ£ÌæÄáÖÎÁƺóÇå¾²ÐÔ²»ÄÍÊܵÄEGFRÍ»±äÍíÆÚNSCLC£¨ACTIVEÑо¿£©

×÷ÕߣºÂ½Ë´  ÉϺ£ÊÐÐØ¿ÆÒ½Ôº

ÕªÒª±àºÅ£ºEP08.03-001

A Clinical Study on the Safety and Efficacy of Aumolertinib Combined with SBRT in the EGFR-mutant NSCLC with Brain Parenchymal Oligometastases

°¢ÃÀÌæÄáÍŽáSBRTÖÎÁÆEGFRÍ»±äNSCLCÄÔʵÖʹÑתÒÆ

×÷ÕߣººØ´ºÓï  ºÓÄÏÊ¡Ö×ÁöÒ½Ôº

Äú¿ÉµÇ¼ÒÔÏÂÍøÖ·£¬£¬£¬£¬£¬Éó²é°¢ÃÀÌæÄá±¾½ìWCLCÈëÑ¡ÕªÒªµÄÏêϸÐÅÏ¢£º
https://library.iaslc.org/conference-program?product_id=25

´Ë´ÎÈëÑ¡µÄ21ƪ°¢ÃÀÌæÄáÕªÒª£¬£¬£¬£¬£¬½«ÓÚ¾Û»áÕÙ¿ªÊ±´úÐû²¼¸ü¶àÐÅÏ¢µÄPoster£¬£¬£¬£¬£¬¾´ÇëÆÚ´ý£¡